Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same

12059,467

18/278416

August 24, 2022

An improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, a preparation method thereof, and a topical sustained release drug delivery formulation including the same are provided. The improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant is obtained by mixing methoxy-free orthoester compounds (classes I and II) in different proportions or mixing an orthoester compound (class I or II) with a biocompatible medical polymer material in different proportions, where an orthoester compound of class I has a chemical formula shown in formula I: [chemical expression included] and an orthoester compound of class II has a chemical formula shown in formula II: [chemical expression included] The present disclosure has the following beneficial effects: In the present disclosure, the biosafety of the pharmaceutical adjuvant is improved by adjusting a substituent type and a length of an orthoester compound, and the properties of the orthoester mixture pharmaceutical adjuvant do not change before and after the improvement.

ANHUI UNIVERSITY (Hefei, CN)

ANHUI UNIVERSITY (Hefei, CN)

1. An improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant obtained by mixing methoxy-free orthoester compounds of class I or mixing a methoxy-free orthoester compound of class I with a biocompatible medical polymer material, wherein the methoxy-free orthoester compound of class I has a chemical formula shown in formula I: [chemical expression included] wherein R 1 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, butyl, and phenyl, and R 2 is selected from the group consisting of ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

2. The improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 1 , wherein a ratio of the methoxy-free orthoester compound of class I to the biocompatible medical polymer material is 1:1,000 to 1,000:1.

3. The improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 1 , wherein the biocompatible medical polymer material is selected from the group consisting of: (i) polycaprolactone (PCL) [chemical expression included] wherein m represents an integer of 2 to 100; (ii) polycaprolactone diol (PCL-diol) [chemical expression included] wherein n represents an integer of 1 to 50; (iii) polylactic acid (PLA) [chemical expression included] wherein x represents an integer of 2 to 100; and (iv) polyethylene glycol (PEG) [chemical expression included] wherein y represents an integer of 2 to 150.

4. The improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 1 , wherein a preparation method of the methoxy-free orthoester compound of class I comprises the following steps: under a protection of nitrogen, dissolving diglycerol, a triester, and a catalyst in a molar ratio of 1:(2.2-5.0):(0.01-0.04) in a first organic solvent, and stirring a resulting solution at room temperature to allow a reaction for 12 h to 48 h; and conducting an extraction with saturated sodium carbonate, drying a resulting extract solution with anhydrous magnesium sulfate, and conducting a vacuum distillation to remove an excess triester to obtain the methoxy-free orthoester compound of class I.

5. The improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 4 , wherein the first organic solvent is selected from the group consisting of acetonitrile, dichloromethane (DCM), tetrahydrofuran (THF), and dioxane; the triester is selected from the group consisting of triethyl orthoformate, triethyl orthoacetate, triethyl orthopropionate, triethyl orthoisopropionate, triethyl orthobutyrate, triethyl orthobenzoate, tripropyl orthoformate, tripropyl orthoacetate, tripropyl orthopropionate, tripropyl orthoisopropionate, tripropyl orthobutyrate, tripropyl orthobenzoate, triisopropyl orthoformate, triisopropyl orthoacetate, triisopropyl orthopropionate, triisopropyl orthoisopropionate, triisopropyl orthobutyrate, triisopropyl orthobenzoate, tributyl orthoformate, tributyl orthoacetate, tributyl orthopropionate, tributyl orthoisopropionate, tributyl orthobutyrate, tributyl orthobenzoate, triisobutyl orthoformate, triisobutyl orthoacetate, triisobutyl orthopropionate, triisobutyl orthoisopropionate, triisobutyl orthobutyrate, triisobutyl orthobenzoate, tri-tert-butyl orthoformate, tri-tert-butyl orthoacetate, tri-tert-butyl orthopropionate, tri-tert-butyl orthoisopropionate, tri-tert-butyl orthobutyrate, and tri-tert-butyl orthobenzoate.

6. A preparation method of the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 1 , comprising the following step: mixing the methoxy-free orthoester compounds of class I or mixing the methoxy-free orthoester compound of class I with the biocompatible medical polymer material, wherein the mixing is conducted at 25° C. to 140° C. under a negative pressure or at 25° C. to 140° C. in a nitrogen atmosphere; or raw materials are first dissolved in a second organic solvent, and then the second organic solvent is removed under a reduced pressure.

7. The preparation method of the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 6 , wherein the second organic solvent is selected from the group consisting of THE, DCM, dioxane, ethanol, methanol, chloroform, acetone, dimethyl sulfoxide (DMSO), and N,N-dimethylformamide (DMF).

8. A topical sustained release drug delivery formulation comprising the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 1 and an active substance, wherein a weight percentage of the active substance is 0.1% to 50%, and a weight percentage of the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant is 50% to 99.9%.

9. The topical sustained release drug delivery formulation according to claim 8 , wherein the active substance is one or more selected from the group consisting of an antitumor drug, an anti-inflammatory drug, a hypoglycemic drug, an antihypertensive drug, an analgesic drug, and a protein vaccine.

10. The topical sustained release drug delivery formulation according to claim 9 , wherein the antitumor drug is one selected from the group consisting of paclitaxel, doxorubicin, gemcitabine, 5-fluorouracil, camptothecin, hydroxycamptothecin, cisplatin, carboplatin, PD-1, gefitinib, erlotinib, sorafenib, and dasatinib.

11. The topical sustained release drug delivery formulation according to claim 9 , wherein the anti-inflammatory drug is one selected from the group consisting of aspirin, sodium diclofenac, ibuprofen, flurbiprofen, ketoprofen, naproxen, indobufen, indomethacin, piroxicam, meloxicam, imrecoxib, celecoxib, dexamethasone, hydrocortisone, prednisolone, methylprednisolone, triamcinolone acetonide, fluocinolone, fludrocortisone, and beclomethasone.

12. The topical sustained release drug delivery formulation according to claim 9 , wherein the antihypertensive drug is selected from the group consisting of a thiazide, a potassium-sparing diuretic, an aldosterone antagonist, a loop diuretic, a central antihypertensive drug, a ganglion-blocking drug, a noradrenergic nerve ending-blocking drug, an adrenoceptor-blocking drug, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor-blocking drug, a renin inhibitor, a dihydropyridine, and a vasodilator.

13. The topical sustained release drug delivery formulation according to claim 9 , wherein the analgesic drug is selected from the group consisting of a receptor agonist, a receptor partial agonist, an opioid receptor antagonist, and an antipyretic analgesic.

14. The topical sustained release drug delivery formulation according to claim 9 , wherein the protein vaccine comprises a natural protein and a chemically-inactivated toxoid.

15. The preparation method of the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 6 , wherein a ratio of the methoxy-free orthoester compound of class I to the biocompatible medical polymer material is 1:1,000 to 1,000:1.

16. The preparation method of the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 6 , wherein the biocompatible medical polymer material is selected from the group consisting of: [chemical expression included] wherein m represents an integer of 2 to 100; [chemical expression included] wherein n represents an integer of 1 to 50; [chemical expression included] wherein x represents an integer of 2 to 100; and [chemical expression included] wherein y represents an integer of 2 to 150.

17. The preparation method of the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 6 , wherein a preparation method of the methoxy-free orthoester compound of class I comprises the following steps: under a protection of nitrogen, dissolving diglycerol, a triester, and a catalyst in a molar ratio of 1:(2.2-5.0):(0.01-0.04) in a first organic solvent, and stirring a resulting solution at room temperature to allow a reaction for 12 h to 48 h; and conducting an extraction with saturated sodium carbonate, drying a resulting extract solution with anhydrous magnesium sulfate, and conducting a vacuum distillation to remove an excess triester to obtain the methoxy-free orthoester compound of class I.

18. The preparation method of the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant according to claim 17 , wherein the first organic solvent is selected from the group consisting of acetonitrile, DCM, THF, and dioxane; the triester is selected from the group consisting of triethyl orthoformate, triethyl orthoacetate, triethyl orthopropionate, triethyl orthoisopropionate, triethyl orthobutyrate, triethyl orthobenzoate, tripropyl orthoformate, tripropyl orthoacetate, tripropyl orthopropionate, tripropyl orthoisopropionate, tripropyl orthobutyrate, tripropyl orthobenzoate, triisopropyl orthoformate, triisopropyl orthoacetate, triisopropyl orthopropionate, triisopropyl orthoisopropionate, triisopropyl orthobutyrate, triisopropyl orthobenzoate, tributyl orthoformate, tributyl orthoacetate, tributyl orthopropionate, tributyl orthoisopropionate, tributyl orthobutyrate, tributyl orthobenzoate, triisobutyl orthoformate, triisobutyl orthoacetate, triisobutyl orthopropionate, triisobutyl orthoisopropionate, triisobutyl orthobutyrate, triisobutyl orthobenzoate, tri-tert-butyl orthoformate, tri-tert-butyl orthoacetate, tri-tert-butyl orthopropionate, tri-tert-butyl orthoisopropionate, tri-tert-butyl orthobutyrate, and tri-tert-butyl orthobenzoate.

19. The topical sustained release drug delivery formulation according to claim 8 , wherein in the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, a ratio of the methoxy-free orthoester compound of class I to the biocompatible medical polymer material is 1:1,000 to 1,000:1.

20. The topical sustained release drug delivery formulation according to claim 8 , wherein in the improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, the biocompatible medical polymer material is selected from the group consisting of: [chemical expression included] wherein m represents an integer of 2 to 100; [chemical expression included] wherein n represents an integer of 1 to 50; [chemical expression included] wherein x represents an integer of 2 to 100; and [chemical expression included] wherein y represents an integer of 2 to 150.

6166137 December 2000 Brown et al.
20090011133 January 2009 Gridnev et al.
20130209566 August 2013 Jablonski et al.
103804339 May 2014
103804684 May 2014
111073002 April 2020
114366711 April 2022
114366711 April 2022
114848585 August 2022
114848585 August 2022

Wang Zhuyong, et al., Application Progress of Prodrug for the Research of the Targeted Antitumor Drugs, Chin J Mod Appl Pharm, 2021, pp. 2323-2332, vol. 38, No. 18. cited by applicant
Tell Tuttle, et al., Hemiortho Esters and Hydrotrioxides as the Primary Products in the Low-Temperature Ozonation of Cyclic Acetals: An Experimental and Theoretical Investigation, J. Am. Chem. Soc., 2004, pp. 16093-16104, vol. 126, No. 49. cited by applicant

edspgr.12059467